Table 5.

Data for 20 comparison group who received Merci/Penumbra treatment.

Patient	Age	Sex	IVtpA	NIH A	% Salvage	Location of clot	Time to intervention	Intervention time	TIMI	Symptomatic ICH	mRS at F/U
1	73	M	1	15	80.7	L M1	7	75	3	Y	2
2	85	F	0	14	73.4	L ICA	10	77	0	N	4
3	53	M	1	11	76.4	R M1	9	69	2	N	4
4	86	F	0	14	59.0	R ICA	8	88	1	N	6
5	47	M	0	14	52.4	R M2	NA	48	0	N	6
6	58	M	0	22	81.0	R M1	6	72	1	N	6
7	49	M	0	21	86.5	L M1	NA	28	3	N	3
8	86	F	1	16	83.2	L M1	4	33	3	N	2
9	63	M	1	12	97.2	R ICA	5	80	3	N	1
10	67	M	0	14	78.7	R M1	5	38	2	N	6
11	59	F	1	15	96.0	R M1	5	65	3	N	2
12	78	M	0	16	27.7	L M1	5	73	2	N	6
13	68	F	0	20	48.8	L ICA	NA	111	3	N	6
14	68	M	1	22	36.8	L M1	4	113	2	Y	6
15	59	F	1	16	58.6	R M1	4	57	1	N	6
16	69	M	1	20	67.5	R ICA	7	100	3	Y	3
17	75	M	0	12	92.6	R M1	4	59	3	N	2
18	59	F	1	12	87.9	R M1	4	85	2	N	6
19	62	M	1	10	92.5	R ICA	7.5	110	3	N	1
20	67	M	1	8	61.7	L M2	5	38	3	N	2
Average					71.9		5.85	70.95